These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 26613512)

  • 1. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
    Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
    Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
    Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
    Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
    Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
    Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway.
    Yu JJ; Zhang Y; Wang Y; Wen ZY; Liu XH; Qin J; Yang JL
    Psychopharmacology (Berl); 2013 Jan; 225(2):361-72. PubMed ID: 22875481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
    Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
    J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transpl Infect Dis; 2019 Aug; 21(4):e13116. PubMed ID: 31102475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
    Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
    Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: Impact of mTOR inhibitors.
    Petrara MR; Serraino D; Di Bella C; Neri F; Del Bianco P; Brutti M; Carmona F; Ballin G; Zanini S; Rigotti P; Furian L; De Rossi A
    Cancer Lett; 2020 Jan; 469():323-331. PubMed ID: 31693921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
    Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
    Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
    Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
    Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burkitt lymphoma after transplant: an aggressive lymphoproliferative disease.
    Akar Özkan E; Özdemir BH; Akdur A; Deniz EE; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():136-8. PubMed ID: 24635811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells.
    Ori Y; Herman-Edelstein M; Zingerman B; Rozen-Zvi B; Gafter U; Malachi T; Gafter-Gvili A
    Biomed Pharmacother; 2012 Sep; 66(6):409-13. PubMed ID: 22795807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
    Thoms KM; Kuschal C; Oetjen E; Mori T; Kobayashi N; Laspe P; Boeckmann L; Schön MP; Emmert S
    Exp Dermatol; 2011 Mar; 20(3):232-6. PubMed ID: 21323745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma.
    Xu L; Zhang M; Tu D; Lu Z; Lu T; Ma D; Zhou Y; Zhang S; Ma Y; Yan D; Wang X; Sang W
    J Pharmacol Exp Ther; 2023 Dec; 387(3):288-298. PubMed ID: 37875309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.
    Navarro-Villarán E; Tinoco J; Jiménez G; Pereira S; Wang J; Aliseda S; Rodríguez-Hernández MA; González R; Marín-Gómez LM; Gómez-Bravo MA; Padillo FJ; Álamo-Martínez JM; Muntané J
    PLoS One; 2016; 11(8):e0160979. PubMed ID: 27518575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.